Survival of patients with chronic acid sphingomyelinase deficiency (ASMD) in the United States: A retrospective chart review study

Ruth Pulikottil-Jacob; Sumudu Dehipawala; Brittany Smith; Amod Athavale; Gaelle Gusto; Aastha Chandak; Artak Khachatryan; Tamar Banon; Marie Fournier; Sophie Guillonneau; Laurence Pollissard; Maria Veronica Munoz-Rojas

doi:10.1016/j.ymgmr.2023.101040

Survival of patients with chronic acid sphingomyelinase deficiency (ASMD) in the United States: A retrospective chart review study

Mol Genet Metab Rep. 2023 Dec 24:38:101040. doi: 10.1016/j.ymgmr.2023.101040. eCollection 2024 Mar.

Affiliations

¹ Sanofi, Reading, United Kingdom.
² Trinity Life Sciences, Waltham, MA, USA.
³ Certara, Paris, France.
⁴ Certara, New York, NY, USA.
⁵ Certara, London, United Kingdom.
⁶ Certara, Montreal, Canada.
⁷ Sanofi, Gentilly, France.
⁸ Sanofi, Cambridge, MA, USA.

Abstract

Background: Acid sphingomyelinase deficiency (ASMD), historically known as Niemann-Pick disease type A, A/B, and B, is a rare lysosomal storage pathology with multisystemic clinical manifestations. The aims of this study were to estimate the survival probability in patients in the United States with chronic ASMD (ASMD types B and A/B), and to describe the disease characteristics of these patients.

Methods: This observational retrospective study included medical chart records of patients with chronic ASMD with retrievable data abstracted by 69 participating physicians from 25 medical centers in the United States. Included patients had a date of ASMD diagnosis or first presentation to a physician for ASMD symptoms (whichever occurred first) between January 01, 1990, and February 28, 2021. Medical chart records were excluded if patients were diagnosed with ASMD type A. Eligible medical chart records were abstracted to collect demographic, medical and developmental history, and mortality data. Survival outcomes were analyzed using Kaplan-Meier survival analyses from birth until death.

Results: The overall study population (N = 110) included 69 patients with ASMD type B, nine with type A/B, and 32 with ASMD "non-type A" (ASMD subtype was unknown, but patients were confirmed as not having ASMD type A). The majority of patients were male with a median age at diagnosis of 3.8 years. Thirty-eight patients died during the study observation period, at a median age of 6.8 years. The median (95% confidence interval) survival age from birth was 21.3 (10.2; 60.4) years. At diagnosis or first presentation, 42.7% patients had ≥1 ASMD-related complication; splenic (30.0%) and hepatobiliary (20.9%) being the most common, and 40.9% required ≥1 medical visit due to complications.

Conclusion: Patients with chronic ASMD in the United States have poor survival and significant burden of illness.

Keywords: Acid sphingomyelinase deficiency; Chart review; Chronic; Mortality; Niemann–Pick disease; Survival analyses.